Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48

Regeneron's global Phase 3 registrational program to be initiated later this year

TARRYTOWN, N.Y., March 09, 2026 (GLOBE NEWSWIRE) --  Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced Hansoh Pharmaceutical Group Company Limited has shared positive topline data from its Phase 3 trial in Chinese patients evaluating olatorepatide for the treatment of adults with obesity or who are overweight. Olatorepatide is a novel dual GLP-1/GIP receptor agonist for which Regeneron has exclusive clinical development and commercial rights outside of the Chinese Mainland, Hong Kong and Macau as part of a strategic in-licensing agreement.

The Phase 3 randomized, double-blind, placebo-controlled trial conducted by Hansoh enrolled 604 adults across 33 clinical sites in mainland China and evaluated once-weekly olatorepatide compared to placebo for 48 weeks. The study assessed four cohorts, including 5 mg, 10 mg or 15 mg olatorepatide and placebo. The trial met its co-primary endpoints, demonstrating that olatorepatide compared to placebo led to a statistically significant reduction in body weight from baseline, and also a statistically significant greater proportion of participants who achieved at least 5% weight loss at 48 weeks. Participants treated with olatorepatide achieved up to a 19% mean weight loss from baseline at week 48. Responder analyses showed that up to 97% of participants achieved ≥5% weight loss at week 48.

Olatorepatide demonstrated a favorable gastrointestinal tolerability in the trial, with lower rates of gastrointestinal adverse events and treatment discontinuation relative to those reported in other published Phase 3 dual incretin trials. The average incidence of nausea was below 10%, and the average incidence of vomiting below 5%.